Eterna Therapeutics Inc
NASDAQ:ERNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eterna Therapeutics Inc
NASDAQ:ERNA
|
US |
|
J&T Global Express Ltd
F:J92
|
CN |
|
Newton Golf Co
NASDAQ:NWTG
|
US |
|
A
|
Aluminum Corp of China Ltd
OTC:ALMMF
|
CN |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
US |
|
P
|
Pennantpark Investment Corp
NYSE:PNNT
|
US |
|
N
|
NETGEAR Inc
XMUN:NGJ
|
US |
|
Bank VTB PAO
MOEX:VTBR
|
RU |
|
Life360 Inc
F:L360
|
US |
|
Bank Tabungan Negara (Persero) Tbk PT
F:TA2
|
ID |
|
H
|
Honeywell International Inc
DUS:ALD
|
US |
|
M
|
Medpal AI PLC
LSE:MPAL
|
UK |
|
Q
|
Quest Diagnostics Inc
SWB:QDI
|
US |
|
Lendlease Global Commercial REIT
SGX:JYEU
|
SG |
|
Altius Renewable Royalties Corp
OTC:ATRWF
|
CA |
|
A
|
Avantor Inc
SWB:AVG
|
US |
|
LXP Industrial Trust
NYSE:LXP
|
US |
|
F
|
Fast Retailing Co Ltd
OTC:FRCOF
|
JP |
Eterna Therapeutics Inc
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. Eterna Therapeutics Inc., formerly Brooklyn ImmunoTherapeutics Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. Eterna Therapeutics Inc., formerly Brooklyn ImmunoTherapeutics Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
